Respiratory News and Research

RSS

Mylan reports total revenues of $1.35 billion for fourth-quarter 2009

Mylan Inc. today announced its financial results for the three and twelve months ended December 31, 2009.

25 Feb 2010

HealthGrades America’s 50 Best Hospitals for 2010 identified

The HealthGrades America’s 50 Best Hospitals for 2010 were identified in a report issued today by the leading independent healthcare ratings organization. The analysis, which examined objective patient outcomes over three years at all 5,000 of the nation’s nonfederal hospitals, found that the 50 Best Hospitals had mortality rates that were, on average, 27% lower than other hospitals.

25 Feb 2010

First convertible endotracheal tube launched by Teleflex Medical

Teleflex Medical has announced the introduction of the Teleflex ISIS™ HVT™, the first convertible endotracheal tube. The Teleflex ISIS HVT features an integrated suction port and separate suction line allowing for subglottic secretion suctioning on demand. Now clinicians can be free from the burden of choosing which tube is best for the patient at the time of intubation. When needed, the suction tube attaches to the Teleflex ISIS HVT via a secure locking connection.

24 Feb 2010

Teleflex's fourth-quarter revenues rise up 4%

Teleflex Incorporated today announced financial results for the fourth quarter and year ended December 31, 2009.

24 Feb 2010

FDA's warning over LABA medications for asthma: AANMA offers guidance

Today Allergy & Asthma Network Mothers of Asthmatics (AANMA) offered guidance to help patients understand recent Food and Drug Administration (FDA) warnings about Advair ® (fluticasone and salmeterol), Foradil ® (formoterol), Severent ® (salmeterol) and Symbicort ® (budesonide and formoterol), daily inhaled medications containing a long-acting beta agonist (LABA, a 12-hour bronchodilator).

24 Feb 2010

New non-neurotoxic treatment for head lice in children

A new non-neurotoxic treatment for head lice has been found to have an average of 91.2% treatment success rate after one week, and to be safe in humans from six months of age and up. This is the finding of a study published today in Pediatric Dermatology.

24 Feb 2010

HealthGrades names Good Samaritan Hospital as One of America’s 50 Best Hospitals in 2010

Good Samaritan Hospital in Los Angeles is named as One of America’s 50 Best Hospitals in 2010 by HealthGrades, Inc., the nation’s leading independent healthcare ratings organization.

24 Feb 2010

Multidisciplinary care teams can also reduce risk of dying in ICUs of hospitals without intensivists

The severe shortage of specially-trained intensivist physicians has hospital intensive care units (ICUs) nationwide struggling to staff units with critical care teams led by intensivists, even though the presence of these specially trained physicians reduces the risk of death for patients in the ICU. A new Penn Medicine report found that replacing intensivist-led teams with multidisciplinary care teams can also reduce the risk of dying in intensive care units. The study appears in the February 22 edition of the Archives of Internal Medicine.

24 Feb 2010

PAREXEL International expands capabilities by opening new early phase unit in Port Elizabeth, South Africa

PAREXEL International Corporation, a leading global biopharmaceutical services provider, today announced that it has expanded its capabilities through the opening of a new early phase unit in Port Elizabeth, South Africa.

From Parexel 24 Feb 2010

Prednisolone associated with recurrence of CAP after its withdrawal

Patients hospitalized with mild to moderate community-acquired pneumonia (CAP) should not be routinely prescribed prednisolone, a corticosteroid, as it is associated with a recurrence of symptoms after its withdrawal, according to the first randomized double-blind clinical trial to address the subject.

24 Feb 2010

FDA grants Diagnostic Hybrids emergency use authorization for 2009 H1N1 Influenza A Virus ID Kit

Diagnostic Hybrids, a Quidel Company has received emergency use authorization from the U.S. Food and Drug Administration for its D3® UltraTM 2009 H1N1 Influenza A Virus ID Kit, a monoclonal antibody fluorescent staining kit for the specific identification of 2009 H1N1 influenza A in direct patient specimens or incubated tissue cultures.

23 Feb 2010

Aradigm initiates dosing in Phase 2b trial of inhaled liposomal ciprofloxacin formulations in BE patients

Aradigm Corporation today announced that it dosed the first patient in the U.S. as part of its ORBIT-1 (Once-daily Respiratory Bronchiectasis Inhalation Treatment) trial, an international, randomized, double-blind, placebo-controlled Phase 2b study designed to evaluate the Company's inhaled liposomal ciprofloxacin (ARD-3100) in patients with non-cystic fibrosis bronchiectasis (BE) under a U.S. IND. This orphan disease indication is a chronic, severe respiratory disease and there are currently no approved treatments for this disease in the U.S.

23 Feb 2010

Multidisciplinary rounds may facilitate implementation of best clinical practices: Study

Multidisciplinary care teams consisting of clinicians, nurses and other health care professionals appear to be associated with a lower risk of death among patients in the intensive care unit, according to a report in the February 22 issue of Archives of Internal Medicine, one of the JAMA/Archives journals. A second report finds that an increasing number of surgical patients are being managed jointly by a surgeon and another clinician, such as a hospitalist or internal medicine sub-specialist.

23 Feb 2010

FDA issues approval for Gileads's Cayston for respiratory symptoms in cystic fibrosis

Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Cayston® (aztreonam for inhalation solution) as a treatment to improve respiratory symptoms in cystic fibrosis patients with Pseudomonas aeruginosa. Cayston’s safety and efficacy have not been established in pediatric patients below the age of 7, patients with forced expiratory volume in one second of less than 25 percent or greater than 75 percent predicted, or patients colonized with Burkholderia cepacia.

23 Feb 2010

Multidisciplinary, team-based approach can reduce mortality rates in ICUs

23 Feb 2010

Hospital-acquired infections increase mortality rate and healthcare costs

Two common conditions caused by hospital-acquired infections (HAIs) killed 48,000 people and ramped up health care costs by $8.1 billion in 2006 alone, according to a study released today in the Archives of Internal Medicine.

23 Feb 2010

Research reveals human Chlamydia pneumoniae has originated from animal source

Animals have been found to have infected humans sometime in the past with the common respiratory disease Chlamydia pneumoniae, according to Queensland University of Technology infectious disease expert Professor Peter Timms.

23 Feb 2010

Gilead Sciences receives FDA approval for new inhaled antibiotic in treatment of CF

The U.S. Food and Drug Administration approved an important new inhaled antibiotic called Cayston® (aztreonam for inhalation solution) today for the treatment of cystic fibrosis. The drug was made possible by significant support from the Cystic Fibrosis Foundation, including a $1 million investment by a Foundation subsidiary to help develop the therapy.

22 Feb 2010

Alnylam Pharmaceuticals initiates ALN-RSV01 Phase IIb trial in adult lung transplant patients for RSV infection

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has initiated a Phase IIb trial in adult lung transplant patients with ALN-RSV01, an RNAi therapeutic for the treatment of respiratory syncytial virus (RSV) infection. RSV infection in lung transplant patients represents an important unmet medical need; the condition is associated with significant morbidity, including the development of acute lung transplant rejection in 10% to 20% of infected patients.

22 Feb 2010

ResMed launches S9 sleep apnoea therapy platform in Europe

ResMed, a leading developer, manufacturer, and distributor of sleep and respiratory medical equipment, today introduced its new cutting-edge sleep apnoea therapy platform called the S9 Series in Europe. The S9 Series combines a sleek design with superior functionality and more comfort. Combined climate control and humidification delivers unsurpassed comfort to the patient by controlling both the temperature and humidity that the patient breathes.

From ResMed Corp 22 Feb 2010

Respiratory News and Research

Mylan reports total revenues of $1.35 billion for fourth-quarter 2009

HealthGrades America’s 50 Best Hospitals for 2010 identified

First convertible endotracheal tube launched by Teleflex Medical

Teleflex's fourth-quarter revenues rise up 4%

FDA's warning over LABA medications for asthma: AANMA offers guidance

New non-neurotoxic treatment for head lice in children

HealthGrades names Good Samaritan Hospital as One of America’s 50 Best Hospitals in 2010

Multidisciplinary care teams can also reduce risk of dying in ICUs of hospitals without intensivists

PAREXEL International expands capabilities by opening new early phase unit in Port Elizabeth, South Africa

Prednisolone associated with recurrence of CAP after its withdrawal

FDA grants Diagnostic Hybrids emergency use authorization for 2009 H1N1 Influenza A Virus ID Kit

Aradigm initiates dosing in Phase 2b trial of inhaled liposomal ciprofloxacin formulations in BE patients

Multidisciplinary rounds may facilitate implementation of best clinical practices: Study

FDA issues approval for Gileads's Cayston for respiratory symptoms in cystic fibrosis

Multidisciplinary, team-based approach can reduce mortality rates in ICUs

Hospital-acquired infections increase mortality rate and healthcare costs

Research reveals human Chlamydia pneumoniae has originated from animal source

Gilead Sciences receives FDA approval for new inhaled antibiotic in treatment of CF

Alnylam Pharmaceuticals initiates ALN-RSV01 Phase IIb trial in adult lung transplant patients for RSV infection

ResMed launches S9 sleep apnoea therapy platform in Europe

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News